Recently, the industry learned that the National Drug Joint Procurement Office issued the "Notice on Convening the National Organization of Drug Centralized Procurement Meeting" on October 10, which means that the tenth batch of drug centralized procurement is coming.
According to the content of the notice, in order to accelerate the process of the tenth batch of centralized procurement of drugs organized by the state, the Office of Joint Procurement of Drugs of the National Organization (State Procurement Office) is scheduled to hold a one-day working meeting on October 15 (Tuesday). According to the notice letter issued by the National Health Insurance Administration, the tenth batch of national procurement catalogue includes a total of 137 products, and the final catalogue is subject to the actual release of the national procurement.
A catalogue of 137 varieties that require feedback on the details of purchase transactions
Among the 137 product catalogs that flowed out, resorcinol injection is a variety that has attracted great attention in centralized procurement. This variety is the most common antispasmodic drug with the most common indications for clinical use, and in the domestic market, resorcinol injection has been approved by 30 pharmaceutical companies, and 29 pharmaceutical companies have been evaluated. According to the pharmaceutical finance cloud database, the sales of this variety in the national hospital market will exceed 800 million yuan in 2023, a year-on-year increase of 11.08%.
Screenshot source: Yaorongyun National Hospital Sales Database
According to the Pharmaceutical Finance Cloud Database, in the national hospital market in 2023, the top 4 companies in resorcinol injection are Nanjing Hengsheng Pharmaceutical, Wanbond Pharmaceutical Group, Wuhan Renfu Pharmaceutical and Chengdu Beite Pharmaceutical, with market shares of 62.39%, 28.57%, 6.96% and 0.04% respectively.
Screenshot source: Yaorongyun National Hospital Sales Database
At the same time, norepinephrine bitartrate injection is also one of the high-profile varieties. Norepinephrine bitartrate injection can constrict splanchnic veins, increase the pressure difference between splanchnic vessels and inferior vena cava, promote blood return to systemic circulation, and increase effective circulatory volume and return blood volume. According to the Pharmaceutical Finance Cloud Database, the sales of this variety in hospitals across the country will exceed 1.5 billion yuan in 2023.
Screenshot source: Yaorongyun National Hospital Sales Database
At present, a total of 15 companies in the domestic market have obtained the production approval of norepinephrine tartrate injection. Among them, 11 companies have passed or are deemed to have passed the consistency evaluation, including Shijiazhuang No. 4 Pharmaceutical, Hainan Beite Pharmaceutical, Hefei Yifan Biopharmaceutical, Shanghai Hefeng Pharmaceutical, and Grand Pharmaceutical.
Screenshot source: Over-rated drug summary database
The tenth batch of national procurement batches not only has the longest time span and covers the largest number of varieties, but also may mark the successful conclusion of the traditional national procurement model! Overall, the outflow list and varieties involved in this collection are mainly concentrated in oral and injection dosage forms, and unfortunately, the breakthrough in external dosage forms has not yet been realized. As the dust settles, it is expected that the reporting work will begin quickly.
<END>